drugset / Trial / NCT00519259

Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

NCT00519259

Phase 1 Unknown 12 enrolled National Institute on Drug Abuse (NIDA)
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.

Timeline

Start
2006-02
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeline Small molecule 30 mg Other
Subject Lobeline Small molecule 45 mg Other
Subject Lobeline Small molecule 60 mg Other